Betta Pharmaceuticals Dirección

Dirección controles de criterios 2/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Lieming Ding

Chief Executive Officer (CEO)

CN¥2.9m

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	11.3yrs
Participación del CEO	0.2%
Permanencia media de la dirección	sin datos
Promedio de permanencia en la Junta Directiva	5yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

Lieming Ding (61 yo)

11.3yrs

Permanencia

CN¥2,900,800

Compensación

Dr. Lieming Ding founded Betta Pharmaceuticals Co., Ltd.(also known as Zhejiang BetaPharma Co., Ltd) in 2002 and serves as its Chairman. Dr. Ding has been Chief Executive Officer and General Manager of Bet...

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Lieming Ding	Founder	no data	CN¥2.90m	0.24% CN¥ 50.9m
Jianxun Fan	VP, CFO & Director	no data	CN¥1.46m	0.031% CN¥ 6.7m
Jiang Wan	Senior VP	5yrs	CN¥2.55m	0.025% CN¥ 5.4m
Jia Tong	Director	no data	CN¥1.46m	0.039% CN¥ 8.5m
Wei Wang	Independent Director	5yrs	CN¥120.00k	sin datos
Cai Jiangnan	Independent Director	5yrs	CN¥120.00k	sin datos
Yangnan Zhang	Chairman of the Supervisory Board & Senior Director of Project Declaration	5yrs	CN¥870.70k	sin datos
Zhihua Yu	Director	5yrs	sin datos	sin datos
Tian Xu	Director	2.1yrs	sin datos	sin datos
Fei Wu	Supervisor	no data	CN¥860.20k	sin datos
Jiajia Xiao	Independent Director	2.1yrs	CN¥120.00k	sin datos
Rong Wang	Shareholder Supervisor	1.9yrs	sin datos	sin datos

5.0yrs

Permanencia media

56.5yo

Promedio de edad

Junta con experiencia: La junta directiva de 300558 se considera experimentada (5 años de antigüedad promedio).

Betta Pharmaceuticals Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Betta Pharmaceuticals Co., Ltd., Annual General Meeting, May 15, 2024

Betta Pharmaceuticals Co., Ltd. Approves Board Elections

Insufficient new directors

High number of new and inexperienced directors

Betta Pharmaceuticals Co., Ltd., Annual General Meeting, Apr 28, 2022

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.45 (vs CN¥0.36 in 3Q 2023)

Investor sentiment deteriorates as stock falls 16%

Betta Pharmaceuticals Co., Ltd. to Report Q3, 2024 Results on Oct 29, 2024

Investor sentiment improves as stock rises 17%

New minor risk - Share price stability

New minor risk - Earnings quality

Second quarter 2024 earnings released: EPS: CN¥0.31 (vs CN¥0.24 in 2Q 2023)

Betta Pharmaceuticals Co., Ltd. to Report First Half, 2024 Results on Aug 06, 2024

Dividend increased to CN¥0.17

Betta Pharmaceuticals Co., Ltd. Announces Final Profit Distribution Plan to Be Implemented on A Shares as Cash Dividend (Tax Included) for the Year 2023, Payable on 06 June 2024

Betta Pharmaceuticals Co., Ltd., Annual General Meeting, May 15, 2024

First quarter 2024 earnings released: EPS: CN¥0.23 (vs CN¥0.12 in 1Q 2023)

Betta Pharmaceuticals Co., Ltd. to Report Q1, 2024 Results on Apr 26, 2024

Investor sentiment improves as stock rises 15%

Investor sentiment improves as stock rises 16%

Betta Pharmaceuticals Co., Ltd. to Report Fiscal Year 2023 Results on Apr 20, 2024

Third quarter 2023 earnings released: EPS: CN¥0.36 (vs CN¥0.02 in 3Q 2022)

Betta Pharmaceuticals Co., Ltd. to Report Q3, 2023 Results on Oct 25, 2023

Second quarter 2023 earnings released: EPS: CN¥0.24 (vs CN¥0.027 in 2Q 2022)

New major risk - Share price stability

Betta Pharmaceuticals Co., Ltd. Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2022, Payable on 15 June 2023

Betta Pharmaceuticals Co., Ltd. Approves Cash Dividend for the Year of 2022

Full year 2022 earnings released: EPS: CN¥0.35 (vs CN¥0.92 in FY 2021)

Betta Pharmaceuticals Co., Ltd. Approves Board Elections

Insufficient new directors

Third quarter 2022 earnings released: EPS: CN¥0.02 (vs CN¥0.32 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.027 (vs CN¥0.16 in 2Q 2021)

Betta Pharmaceuticals Co., Ltd. announced that it expects to receive CNY 999.999991 million in funding

Investor sentiment improved over the past week

Betta Pharmaceuticals Co., Ltd. Announces Cash Dividend for 2021, Payable on 30 May 2022

First quarter 2022 earnings released: EPS: CN¥0.20 (vs CN¥0.36 in 1Q 2021)

High number of new and inexperienced directors

Betta Pharmaceuticals Co., Ltd., Annual General Meeting, Apr 28, 2022

Betta Pharmaceuticals Co., Ltd. Proposes Final Cash Dividend for 2021

Full year 2021 earnings released: EPS: CN¥0.92 (vs CN¥1.50 in FY 2020)

Third quarter 2021 earnings released: EPS CN¥0.32 (vs CN¥0.92 in 3Q 2020)

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS CN¥0.16 (vs CN¥0.033 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.36 (vs CN¥0.33 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥1.50 (vs CN¥0.58 in FY 2019)

New 90-day low: CN¥95.46

Investor sentiment deteriorated over the past week

Betta Pharmaceuticals Co., Ltd. to Report Fiscal Year 2020 Results on Mar 26, 2021

New 90-day high: CN¥120

Market pulls back on stock over the past week

Third quarter earnings released

Third-quarter earnings released: Revenue beats expectations

New 90-day low: CN¥108

New 90-day low - CN¥110

Ningbo Kaiming Innovation Technology Co., Ltd. completed the acquisition of Zhejiang Betta Pharmaceutical Technology Co., Ltd. from Betta Pharmaceuticals Co., Ltd. (SZSE:300558).

Earnings released

Betta Pharmaceuticals Co., Ltd. to Report First Half, 2020 Results on Aug 06, 2020

Betta Pharmaceuticals Co., Ltd. announced that it expects to receive CNY 1.002 billion in funding

CEO

Permanencia

Compensación

Miembros de la Junta

Permanencia media

Promedio de edad